infectious diseases

News

GSK preps filings for chronic hepatitis B drug bepirovirsen

GSK will file its chronic hepatitis B virus therapy bepirovirsen for approval in the first quarter, after it hit the mark in two phase 3 trials.

R&D

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

News

Acting CDC director and former tech investor Jim O'Neill

CDC signs off on advice ending universal hepatitis B jabs

Overturning decades of advice, the CDC has said it no longer recommends that all US newborns receive a hepatitis B vaccine.

News

CHMP decision levels the playing field for GSK's RSV jab

GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

News

Are RSV shots next in line for restrictions in the US?

After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.

News

GSK pumps £45m into antimicrobial resistance projects

GSK has revealed the six projects it will fund with the Fleming Initiative on antimicrobial resistance, set up with Imperial College London last year.

GSK preps filings for chronic hepatitis B drug bepirovirsen

Q4 Clinical trials round-up: October to December 2025

CDC signs off on advice ending universal hepatitis B jabs

CHMP decision levels the playing field for GSK's RSV jab

Are RSV shots next in line for restrictions in the US?

GSK pumps £45m into antimicrobial resistance projects

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

infectious diseases

Editor's Picks